Page 280 - Pagetit

INDEX

MRI, see Magnetic resonance imaging
Mu opioid receptor 137
Mu receptor agonists 79

Naloxone, treatment of opioid dependence 83–84
Naltrexone
and alcohol abuse 72
treatment of opioid dependence 83–84
Narcolepsy, amphetamine treatment 94, 96
Neurobiology, shared hypothesis of substance use 170–171, 188–191
Neuroimaging 39–40
Neuroleptics
and dopamine function 175
dopamine receptor antagonists 177
schizophrenia
clozapine 175–176
side-effects 172
Neuron anatomy and organization 25–29
Neuropeptide Y, neurotransmission in depression 187
Neurotransmission 29–31
Neurotransmitters 32–35
defined 32
examples 33–35
release 30–31
Nicotine (see also Tobacco) 107
dopamine levels in frontal cortex 178
half-life 75
mechanism of action 76–77
metabolism 131–132
Nicotinic receptors
acetylcholine alpha-7 179–180
beta-2 131
NMDA, see N-Methyl-D-aspartate
NMDA glutamate receptor antagonist, phencyclidine (PCP) 109, 178–179
Norepinephrine 34
Nucleus accumbens (see also Dopamine) 24, 177
dopamine receptors, DRD3 142–143
“shell” region 51, 87

Opioid metabolizing enzymes 138
Opioid receptors 147
kappa receptor 80, 137
mu receptor 137
Opioids 79–84, 107
adaptations to prolonged use 81

259

Index 259 19.1.2004, 11:52